步长制药：关于全资子公司经营范围变更的公告

Core Viewpoint - On November 7, 2025, the company announced the approval of a change in the business scope of its wholly-owned subsidiary, Yangling Buchang Pharmaceutical Co., Ltd., during the 35th meeting of the fifth board of directors, which was held via telecommunication [1]. Group 1 - The board meeting received a unanimous vote with 8 votes in favor, 0 against, and 0 abstentions [1]. - The change in business scope is driven by the operational management needs of the subsidiary [1].